ANTIMICROBIAL RESISTANCE SOLUTIONS
WITH DR. JOHN H. REX
Latest Newsletters
Latest Government Action





















R&D Insight
Can you help?
Antimicrobial resistance poses a catastrophic threat. If we don’t act now, any one of us could go into hospital in 20 years for minor surgery and die because of an ordinary infection that can’t be treated by antibiotics. And routine operations like hip replacements or organ transplants could be deadly because of the risk of infection.
Dame Sally Davies Tweet
De-risking vaccine development: Insights spanning decades of experience
How hard (and how) to Pull? Net value of Pull via a Transferrable Exclusivity Extension (TEE)
Novel Biology, Novel Utility, & the Illusion of Skill: What to develop? What to reward?
Categories of resistance: MDR, XDR, PDR, UDR, and (new!) DTR
FDA Workshop: Animal Models To Support Antibacterial Development (5 Mar 2020, post-meeting notes)
Anti-Gram-negative beta-lactams in jeopardy: The rise of PBP3 mutations
Chemical vs. drugs (Part 2): How do you discriminate? / More on halicin
COVID-19 and the Long-Term Trajectory of AMR Efforts: Wellcome Trust Deep Dive
Language matters: CRE vs. CPE; SDD vs. I; and MDR, XDR, PDR, UDR vs. DTR
Impact of PASTEUR: 9.9m lives saved, ROI of 125:1
New pipeline analysis: Cancer projects were funded 17x more than antibacterials during 2011-2020
News from Davos 2020: Some positive signs, but overall a fragile antibiotic market at a tipping point
The thoughtless person playing with penicillin treatment is morally responsible for the death of the man who succumbs to infection with the penicillin-resistant organism.
Alexander Fleming Tweet
The bipartisan PASTEUR Act is the strongest bill ever written to strengthen antibiotic development and use. It will fix our market failures, expand the pipeline for next generation antibiotics, and save lives. We can’t sit on our hands as this public health crisis arrives – we have to act now.
U.S. Senator Michael Bennet Tweet